Anterogen
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Anterogen is a South Korean biotech listed on KOSDAQ that develops and produces stem-cell-based therapies, treatments that use the body's own repair cells to address diseases that conventional medicine struggles to treat.
Its products are used by patients with conditions such as Crohn's disease-related fistulas and other rare or hard-to-treat illnesses. A key structural fact is that the company operates two distinct revenue streams: it develops and commercialises its own stem-cell therapies, and it also holds the domestic Korean distribution rights for two pulmonary arterial hypertension drugs, which it supplies exclusively in Korea.
Summary is AI-generated and may contain errors · figures from DART filings
Anterogen holds the Korean regulatory approval and exclusive domestic distribution rights for the pulmonary hypertension treatments Remodulin and Tyvaso, making it both a drug developer and a licensed distributor.
Anterogen in five facts
What does Anterogen do?
Anterogen is a South Korean biotech listed on KOSDAQ that develops and produces stem-cell-based therapies, treatments that use the body's own repair cells to address diseases that conventional medicine struggles to treat.
Where is Anterogen listed and in which sector?
Anterogen (Korean name: 안트로젠) trades under KRX code 065660 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Industrials sector, Trading & Distribution.
How large is Anterogen?
Its market capitalisation was US$109.8M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Anterogen's latest annual revenue and operating profit?
For fiscal year 2025, Anterogen reported revenue of US$5.7M, an operating loss of US$1.8M and a net loss of US$1M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 8.7% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.